Merck Cervical Cancer Vaccine listed! There are 11 pharmaceutical companies are lining up

Pharmaceutical Network November 10 following the GSK Simai Shi after the mainland China's second cervical cancer vaccine - Merck four-price Jia Da Xiu, in some provinces and cities have been open appointment, at least 32.2 billion in the Mainland Market, smoke from the beginning.

Needless to say, there are already 11 domestic pharmaceutical companies submitting clinical applications for cervical cancer vaccines and the Merck East Kowloon-Vat Vaccine under review.

Recently, according to media reports, in early November, the four-price cervical cancer vaccine (hereinafter referred to as 'four-valent HPV vaccine') was officially listed on the mainland and one after another into the provinces Bidding purchase channel.

According to Cyberjaya, at present, only the cervical cancer vaccine approved by both GSK and Merck & Sidon is approved and listed in the world. Merck's four-price Jia Da Xiu, Ji Jia Jia Da Xiu, GlaxoSmithKline Xi Rui suitable price.

Cerberus blue also learned that Merck's quadrivalent HPV vaccine has begun to participate in the bidding around, in Yunnan, Chongqing, Henan, Jiangxi, Hubei, Heilongjiang and other six provinces have won the bid, the price of 798 yuan / support.

From the effect of view, the bivalent cervical cancer vaccine can prevent 16, 18 two kinds of HPV virus, at the same time can cross-protect type 31, 33, 45 virus; four cervical cancer vaccine can be used to prevent 6, 11, 16, 18 four kinds of HPV According to the popular saying, the higher the 'price' is, the better the prevention is and the more expensive it is.

From the price level, has sold 4 months of GSK two price Xirui 580 yuan, Mermaid four-price Jia Tatsuo repair 798 yuan, a single high price of nearly 40%.

Judging from the scope of application, GSK products range from 9 to 25 years of age, while Merck's products range from 20 to 45 years of age. That is, the overlapping age groups of competitors are between 20 and 25 years of age.

Age also relates to spending power and vaccination effectiveness.According to the World Health Organization recommended that the main vaccination of cervical cancer vaccine population is 9-13 years old female , While secondary vaccination groups are larger female adolescents and young women, although vaccination effectiveness will diminish with age, but the affordability of older age groups is also relatively strong.

Judging from market opportunities, GSK's Sirito listed in the mainland market as early as four-price Jia Da repair 5 months or so July 31, Sirito market, and soon after, GSK Ally to seize the market.

According to GSK, the cooperation projects cover more than 150 community health service centers in 40 cities - it is estimated that by the end of this year, it will cover hundreds of cities including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing and Wuhan all over the country Of 1,500 community health service centers.

Merck lost the market opportunities are not to be outdone hands Chi-fly creatures.

Merck signed an agreement with the Zhifei biological, the two sides agreed that Merck's quadruple HPV vaccine Jia Da repair listing, the Zhifei biological responsible for Jia Da Xiu in mainland China's import, promotion and sales work, Zhifei biological possession of the product exclusive proxy right.

It is understood that, at present, Harbin, Nanjing, Zhengzhou and other places have gradually started the prevalent vaccination of the quadrivalent HPV vaccine.

At the latest, with the gunpowder sound of the new year, GSK and Merck's war in the HPV market will start .Many local pharmaceutical companies are also seeking Fengeng.

At present, 11 pharmaceutical companies in China have submitted clinical applications for HPV vaccines, of which 3 are tetravalent vaccines, 1 is hexavalent vaccines, 4 are nine vaccines and 9 are also under evaluation.

It is not hard to imagine that after the local pharmaceutical companies have made any attempt to become a 'producer,' a price war is inevitable. According to market estimates, the fastest Shanghai Ze Run (Watson's) HPV vaccine will not be able until 2019 Listing, then, with GSK and Merck, the market situation may not be too optimistic.

However, fortunately, according to the analysis of the industry continued heavy volume will be a trend.

According to data from the Frontier Industry Institute, if the HPV vaccine reaches 5% penetration rate in the Chinese market, the market capacity of the domestic HPV vaccine will reach 32.2 billion, which will have a huge space.

In addition, in addition to a broad range of adult vaccination needs, some regional governments have plans to cover the second category of vaccines, and the inclusion of the second category of vaccines into the immunization program should be a national trend as the financial viability of government agencies continues to grow.

In addition to policy factors, consumers health Consciousness, the reality of the rising affordability can not be ignored.After previous media reports, Hong Kong's nine cervical cancer vaccine was in short supply caused the out of stock.After all, cervical cancer is the only cracked cancer in the world, vaccination can play Prevention effect.

With the expansion of cervical cancer vaccine market, a 'Central Plains' fight melee, inevitable.